TRPA1: Better Target for CF Therapy?November 10, 2016 at 2:22 pm
By Paul Schumacker, PhD, editor, American Journal of Respiratory Cell and Molecular Biology
Follow Dr. Schumacker on Twitter @ATSRedEditor
Currently available drugs reduce the lung tissue damage caused by the recurrent bacterial infections and inflammatory responses in patients with cystic fibrosis, but the drugs’ efficacy is limited and not without side effects. In their November American Journal of Respiratory Cell and Molecular Biology article, Paola Prandini and colleagues report findings of an in vitro study to determine if Transient Receptor Potential Ankyrin 1 (TRPA1) calcium channels would be a better therapeutic target. They found that inhibition of TRPA1 expression reduces release of several cytokines in CF epithelial cells exposed to Pseudomonas aeruginosa infection, suggesting these channels may be a target for drugs that could reduce tissue damage “without completely blunting the immune response.”
The ATS unveiled a newly redesigned Journals website. Explore now!